Pacira BioSciences, Inc. (PCRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pacira BioSciences, Inc. (PCRX) has a cash flow conversion efficiency ratio of 0.039x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($25.68 Million) by net assets ($653.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Pacira BioSciences, Inc. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Pacira BioSciences, Inc. - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Pacira BioSciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pacira BioSciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pacira BioSciences, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wuhan LinControl Automotive Electronics Co. Ltd. A
SHG:688667
|
0.053x |
|
Saul Centers Inc
NYSE:BFS
|
0.062x |
|
MeiraGTx Holdings PLC
NASDAQ:MGTX
|
-8.050x |
|
MHP SE GDR S/2
F:MPQ
|
0.056x |
|
Grupa Pracuj S.A.
WAR:GPP
|
0.138x |
|
ASGN Inc
NYSE:ASGN
|
0.047x |
|
Ningbo Runhe High-Tech Materials Co Ltd Class A
SHE:300727
|
0.061x |
|
Run Long Construction Co Ltd
TW:1808
|
0.308x |
Annual Cash Flow Conversion Efficiency for Pacira BioSciences, Inc. (2008–2025)
The table below shows the annual cash flow conversion efficiency of Pacira BioSciences, Inc. from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see Pacira BioSciences, Inc. (PCRX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $693.11 Million | $151.99 Million | 0.219x | -9.88% |
| 2024-12-31 | $778.35 Million | $189.39 Million | 0.243x | +36.90% |
| 2023-12-31 | $870.13 Million | $154.65 Million | 0.178x | -5.18% |
| 2022-12-31 | $775.01 Million | $145.27 Million | 0.187x | +8.91% |
| 2021-12-31 | $730.41 Million | $125.72 Million | 0.172x | +38.46% |
| 2020-12-31 | $619.69 Million | $77.03 Million | 0.124x | -37.43% |
| 2019-12-31 | $354.94 Million | $70.52 Million | 0.199x | +30.59% |
| 2018-12-31 | $321.23 Million | $48.87 Million | 0.152x | +139.07% |
| 2017-12-31 | $279.48 Million | $17.79 Million | 0.064x | -58.35% |
| 2016-12-31 | $218.98 Million | $33.45 Million | 0.153x | +15.06% |
| 2015-12-31 | $218.39 Million | $29.00 Million | 0.133x | -10.78% |
| 2014-12-31 | $171.15 Million | $25.47 Million | 0.149x | +114.20% |
| 2013-12-31 | $41.25 Million | $-43.22 Million | -1.048x | +1.62% |
| 2012-12-31 | $65.86 Million | $-70.13 Million | -1.065x | -65.81% |
| 2011-12-31 | $48.27 Million | $-31.00 Million | -0.642x | -224.89% |
| 2010-12-31 | $-48.38 Million | $-24.88 Million | 0.514x | -43.37% |
| 2009-12-31 | $-22.95 Million | $-20.84 Million | 0.908x | +123.30% |
| 2008-12-31 | $7.49 Million | $-29.19 Million | -3.897x | -- |
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension ind… Read more